Home » Newsletters » BioWorld Science

BioWorld Science

June 4, 2013

View Archived Issues

Preliminary results of phase I/II trial of novel gene therapy for Wiskott-Aldrich syndrome

New durable submucosal gel to aid endoscopic gastric lesion removal

FXR agonist shows potential for the treatment of hypertension and insulin resistance

CR-4056 reduces experimental postoperative pain

MEDI-551 shows efficacy in patients with CLL

First patients treated in Bioheart's ANGEL study

Exelixis commences pivotal phase III METEOR trial

Roswell Park Cancer Institute and Jasco Pharmaceuticals enter collaboration

European CHMP recommends approval of Teva's Lonquex

Algeta launches anticancer drug Xofigo in the U.S.

Preclinical and phase I results for VTX-2337 in ovarian cancer

Qiagen expands its pipeline of personalized healthcare companion diagnostics

AstraZeneca initiates large studies of biomarker role in NSCLC

AstraZeneca receives MJFF grant to study treatment for LID

FDA grants fast track designation to SGX-942

Merck Serono to collaborate with BeiGene on BeiGene-283

NeuroDiscovery changes name to OncoSil Medical Ltd.

Isis Pharmaceuticals earns milestone payment from AstraZeneca for ISIS-ARRx

Researchers at Actelion disclose new NPS receptor antagonists

Lucentis receives positive CHMP opinion in myopic choroidal neovascularization

Astellas Pharma presents novel RSK inhibitors

New Chk1 inhibitors disclosed by Sentinel Oncology

Bavarian Nordic's smallpox vaccine receives positive opinion from CHMP

Intervet International prepares new DGAT1 inhibitors

Novel oral agent for bowel cleansing launched in Japan

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...